We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Whole Genome Test Pinpoints Mutations in Neonates

By LabMedica International staff writers
Posted on 15 Oct 2012
A prototype whole genome sequencing test on blood sample that only takes 50 hours has been developed for neonatal intensive care units (NICU) enabling doctors to diagnose genetic diseases. More...


There are at least 3,500 known genetic diseases caused by mutations in DNA, and treatments are available for more than 500 of them but currently it takes about a month to get the sort of results that allow pediatricians to make a definitive diagnosis.

Scientists at the Children's Mercy Hospital (Kansas City, MO, USA) used a whole genome sequencing (WGS) program they developed themselves called STAT-Seq, in conjunction with a sequencing machine, to cast a broad net over the 3,500 or so known genetic diseases and achieve results in time for doctors to make clinical decisions.

The prototype was tested by doing retrospective 50-hour WGS on two children whose molecular diagnoses had already been done the conventional way. Then the scientists did tests on children not tested before, and confirmed the results by sequencing genomes of parents and siblings. These tests revealed, in one newborn a severe Gap junction beta-2 protein (GJB2)-related skin disease. In another they uncovered Breast Cancer (BRCA1)-associated ataxia telangiectasia mutated (ATM) activator 1(BRAT1)-related lethal neonatal rigidity and multifocal seizure syndrome. They also found other gene defects in additional children, including a new disease-causing mutation, B-cell lymphoma 9-like protein (BCL9L).

The investigators have cut down the time by developing statistical software that matches up doctors' unique descriptions of the patient's condition and symptoms, against a comprehensive set of relevant diseases while looking at the genome test results. By allowing the individual features to be entered, the software substantially automates identification of the DNA variations that can explain the child's condition. The program they developed themselves, the STAT-Seq, was used in conjunction with a HiSeq 2500 sequencing machine (Illumina Inc., San Diego, CA, USA).

The authors concluded that rapid WGS can potentially broaden and foreshorten differential diagnosis, resulting in fewer empirical treatments and faster progression to genetic and prognostic counseling. By shortening the time-to-diagnosis, they may markedly reduce the number of other tests performed and reduce delays to a diagnosis, as reaching an accurate diagnosis quickly can help to shorten hospitalization and reduce costs and stress for families. The study was published on October 3, 2012, in the journal Science Translational Medicine.

Related Links:

Children's Mercy Hospital
Illumina Inc.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.